Brief: TCR Therapeutics Announces Clinical Trial Collaboration Agreement With Bristol Myers Squibb
25/10/2021 12:01
Oct 25 (Reuters) - Bristol-Myers Squibb Co BMY.N :
* TCR² THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION
AGREEMENT WITH BRISTOL MYERS SQUIBB TO EVALUATE GAVO-CEL IN
COMBINATION WITH OPDIVO® AND YERVOY® IN MESOTHELIN-EXPRESSING
SOLID TUMORS
Source text for Eikon: ID:nGNX94DVRp
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview